Seeking Alpha
 

Novavax, Inc. (NVAX)

- NASDAQ
  • Mar. 1, 2013, 8:03 AM
    Novavax (NVAX): Q4 EPS of -$0.06 misses by $0.01. Revenue of $4.56M misses by $2.48M. (PR)
    | 1 Comment
  • Mar. 1, 2013, 12:05 AM
    Notable earnings before Friday’s open: AMRC, BBY, EVEP, FWLT, HPT, MGA, NVAX, POM, XLS
    | Comment!
  • Feb. 28, 2013, 5:30 PM
    Notable earnings before Friday’s open: AMRC, BBY, EVEP, FWLT, HPT, MGA, NVAX, POM, XLS
    | Comment!
  • Nov. 2, 2012, 8:05 AM
    Novavax (NVAX): Q3 EPS of -$0.05 in-line. Revenue of $5.8M (+16% Y/Y) misses by $2M. (PR)
    | Comment!
  • Nov. 2, 2012, 12:05 AM
    Notable earnings before Friday’s open: ALU, ANR, ARCO, BEAM, BGCP, BPL, BPO, CTB, CVX, DNDN, FIG, HES, HUN, ITT, MHP, NI, NRF, NRG, NVAX, NVE, RL, SEE, SSYS, TRI, VIAB, VRX, WCRX, XEC, YRCW
    | Comment!
  • Nov. 1, 2012, 5:30 PM
    Notable earnings before Friday’s open: ALU, ANR, ARCO, BEAM, BGCP, BPL, BPO, CTB, CVX, DNDN, FIG, HES, HUN, ITT, MHP, NI, NRF, NRG, NVAX, NVE, RL, SEE, SSYS, TRI, VIAB, VRX, WCRX, XEC, YRCW
    | Comment!
  • Oct. 18, 2012, 11:52 AM
    Novavax (NVAX +3.5%) gains after saying that Phase I clinical studies of it's investigational avian influenza vaccine met their primary objectives of safety and immune response.
    | Comment!
  • Oct. 18, 2012, 9:10 AM
    Premarket gainers: GIVN +13%. WCC +11%. SVU +9%. JNPR +7%. NVAX +7%. MGM +6%. AEGR +5%.
    Losers: MNKD -25%. CYTR -20%. ALGN -20%. IMUC -18%. LXRX -16%. MLNX -15%. GORO -14%. CDR -7%. SCSS -7%. VRNG -6%.
    | 1 Comment
  • Aug. 3, 2012, 8:12 AM
    Novavax (NVAX): Q2 EPS of -$0.05 beats by $0.02. Revenue of $7.1M (+137% Y/Y) beats by $0.2M. (PR)
    | Comment!
  • Aug. 3, 2012, 12:05 AM
    Notable earnings before Friday’s open: BPL, BPO, BZH, ELT, HNT, IMGN, ITT, NVAX, NYX, PG, WCG, WCRX, YRCW
    | Comment!
  • Aug. 2, 2012, 5:30 PM
    Notable earnings before Friday’s open: BPL, BPO, BZH, ELT, HNT, IMGN, ITT, NVAX, NYX, PG, WCG, WCRX, YRCW
    | Comment!
  • Jul. 5, 2012, 10:07 AM
    Novavax (NVAX) provides a positive report from the Phase I trial of what would be the first vaccine for respiratory syncytial virus (RSV), which causes pneumonia, as well as bronchiolitis in babies. Shares -3.5% but they've been rising since the middle of June. (PR)
    | Comment!
  • May 4, 2012, 8:28 AM
    Novavax (NVAX): Q1 EPS of -$0.06 misses by $0.02. Revenue of $4.64M (+475% Y/Y) beats by $0.2M. Shares +6.7% premarket. (PR)
    | 1 Comment
  • Mar. 9, 2012, 8:09 AM
    Novavax (NVAX): Q4 EPS of -$0.03 beats by $0.01. Revenue of $5.85M misses by $1M. Shares +3.8% premarket. (PR)
    | Comment!
  • Jan. 23, 2012, 12:15 PM
    Shares of vaccine maker Novavax (NVAX +5.4%) surge as nine people die from an outbreak of swine flu in Mexico, with the number of cases almost doubling in a week. Earlier this month, 12 American citizens were reported as infected with H1N1 flu, with fears that the virus had mutated to H3N2v - the strain transmitted from human-to-human.
    | Comment!
  • Oct. 5, 2011, 1:39 PM
    Bio-pharmaceutical developer Novavax (NVAX +4%) trades higher after winning a $1.3M contract from the U.S. Department of Homeland Security to develop a virus-like particle vaccine countermeasure to protect against foot-and-mouth disease.
    | Comment!
Visit Seeking Alpha's
NVAX vs. ETF Alternatives
Company Description
Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
Sector: Healthcare
Industry: Biotechnology
Country: United States